Based on the STARPHARMA HLDG.SP.ADR/10 stock forecast from 0 analysts, the average analyst target price for STARPHARMA HLDG.SP.ADR/10 is not available over the next 12 months. STARPHARMA HLDG.SP.ADR/10’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of STARPHARMA HLDG.SP.ADR/10 is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, STARPHARMA HLDG.SP.ADR/10’s stock price was EUR 0.58. STARPHARMA HLDG.SP.ADR/10’s stock price has changed by -10.85% over the past week, -9.45% over the past month and -45.24% over the last year.
No recent analyst target price found for STARPHARMA HLDG.SP.ADR/10
No recent average analyst rating found for STARPHARMA HLDG.SP.ADR/10
Company Overview STARPHARMA HLDG.SP.ADR/10
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. Read Less
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company's products include VivaGel BV, a non-antibiotic vaginal gel ...Read More
Frequently Asked Questions About STARPHARMA HLDG.SP.ADR/10 (PQ6A:F) Stock
Stock Target Advisor's fundamental analysis for STARPHARMA HLDG.SP.ADR/10's stock is Very Bearish.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate if its overvalued.
The last closing price of PQ6A:F's stock was EUR 0.58.
The most recent market capitalization for PQ6A:F is EUR 0.03B.
Unfortunately we do not have enough analyst data on PQ6A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains STARPHARMA HLDG.SP.ADR/10's stock.
As per our most recent records STARPHARMA HLDG.SP.ADR/10 has 40 Employees.
STARPHARMA HLDG.SP.ADR/10's registered address is 4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067.
You can get more information about it from STARPHARMA HLDG.SP.ADR/10's website at https://starpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About STARPHARMA HLDG.SP.ADR/10 (PQ6A:F) Stock
Stock Target Advisor's fundamental analysis for STARPHARMA HLDG.SP.ADR/10's stock is Very Bearish.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PQ6A:F's stock to indicate if its overvalued.
The last closing price of PQ6A:F's stock was EUR 0.58.
The most recent market capitalization for PQ6A:F is EUR 0.03B.
Unfortunately we do not have enough analyst data on PQ6A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains STARPHARMA HLDG.SP.ADR/10's stock.
As per our most recent records STARPHARMA HLDG.SP.ADR/10 has 40 Employees.
STARPHARMA HLDG.SP.ADR/10's registered address is 4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067.
You can get more information about it from STARPHARMA HLDG.SP.ADR/10's website at https://starpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PQ6A:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
